Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (51-60 of 184) with videos related to

Pageof 19
Sort By:
Journal of the International AIDS Society|July 13, 2023
U.S. patient preferences for long-acting HIV treatment: a discrete choice experimentSusan M Graham, Douglas Barthold, Brett Hauber, et al.
Brain : a Journal of Neurology|June 30, 2022
Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virusRonald J Ellis, Ned Sacktor, David B Clifford, et al.
Annals of Clinical and Translational Neurology|July 4, 2020
Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIVRonald J Ellis, Monica Diaz, Ned Sacktor, et al.
HIV Clinical Trials|December 17, 2013
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202Philip M Grant, Camlin Tierney, Chakra Budhathoki, et al.
Journal of Pharmaceutical Sciences|February 2, 2020
Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101Simone Perazzolo, Laura M Shireman, Lisa A McConnachie, et al.
The Journal of Infectious Diseases|November 14, 2012
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease statusKatie Mollan, Eric S Daar, Paul E Sax, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2014
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202Charles S Venuto, Katie Mollan, Qing Ma, et al.
Journal of the International Association of Providers of AIDS Care|March 9, 2021
"Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal KenyaJane M Simoni, Kristin Beima-Sofie, George Wanje, et al.
AIDS (London, England)|August 28, 2007
The prevalence and incidence of neurocognitive impairment in the HAART eraKevin R Robertson, Marlene Smurzynski, Thomas D Parsons, et al.
AIDS Care|January 25, 2021
Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settingsThiago S Torres, Linda J Harrison, Alberto M La Rosa, et al.
Pageof 19

Showing results (51-60 of 184) with videos related to

Sort By:
Pageof 19
Journal of the International AIDS Society|July 13, 2023
U.S. patient preferences for long-acting HIV treatment: a discrete choice experimentSusan M Graham, Douglas Barthold, Brett Hauber, et al.
Brain : a Journal of Neurology|June 30, 2022
Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virusRonald J Ellis, Ned Sacktor, David B Clifford, et al.
Annals of Clinical and Translational Neurology|July 4, 2020
Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIVRonald J Ellis, Monica Diaz, Ned Sacktor, et al.
HIV Clinical Trials|December 17, 2013
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202Philip M Grant, Camlin Tierney, Chakra Budhathoki, et al.
Journal of Pharmaceutical Sciences|February 2, 2020
Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101Simone Perazzolo, Laura M Shireman, Lisa A McConnachie, et al.
The Journal of Infectious Diseases|November 14, 2012
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease statusKatie Mollan, Eric S Daar, Paul E Sax, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2014
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202Charles S Venuto, Katie Mollan, Qing Ma, et al.
Journal of the International Association of Providers of AIDS Care|March 9, 2021
"Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal KenyaJane M Simoni, Kristin Beima-Sofie, George Wanje, et al.
AIDS (London, England)|August 28, 2007
The prevalence and incidence of neurocognitive impairment in the HAART eraKevin R Robertson, Marlene Smurzynski, Thomas D Parsons, et al.
AIDS Care|January 25, 2021
Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settingsThiago S Torres, Linda J Harrison, Alberto M La Rosa, et al.
Pageof 19